Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Reduced in vivo high-energy phosphates precede Adriamycin-induced cardiac dysfunction

22 May 2010

Abstract excerpt

Adriamycin (ADR) is an established, life-saving antineoplastic agent, the use of which is often limited by cardiotoxicity. ADR-induced cardiomyopathy is often accompanied by depressed myocardial high-energy phosphate (HEP) metabolism. Impaired HEP metabolism has been suggested as a potential mechanism of ADR cardiomyopathy, in which case the bioenergetic decline should precede left ventricular (LV) dysfunction....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cardiovascular Function and Risk Factors
Share to Chemotherapy-induced cardiotoxicity and mitigation
Share to Magnesium in Health and Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 20495142
DOI: 10.1152/ajpheart.00727.2009

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Reduced in vivo high-energy phosphates precede Adriamycin-induced cardiac dysfunctionPMID 20495142Read ↗

In vivo 2D mapping of impaired murine cardiac energetics in NO‐induced heart failureSemantic proximity Read ↗

Cardiac energetics are abnormal in Friedreich ataxia patients in the absence of cardiac dysfunction and hypertrophy: An in vivo 31P magnetic resonance spectroscopy studySemantic proximity Read ↗

Influence of metabolic dysfunction on cardiac mechanics in decompensated hypertrophy and heart failure.Semantic proximity Read ↗

Abnormal cardiac energetics in patients carrying the A3243G mtDNA mutation measured in vivo using phosphorus MR spectroscopy.Semantic proximity Read ↗

Unchanged mitochondrial organization and compartmentation of high-energy phosphates in creatine-deficient GAMT-/- mouse hearts.Semantic proximity Read ↗

Diastolic dysfunction and altered energetics in the alphaMHC403/+ mouse model of familial hypertrophic cardiomyopathy.Semantic proximity Read ↗

Hyperpolarized 13C Magnetic Resonance Reveals Early- and Late-Onset Changes to <i>in vivo</i> Pyruvate Metabolism in the Failing HeartSemantic proximity Read ↗

PCr/ATP ratios and mitochondrial function in the heart. A comparative study in humansSemantic proximity Read ↗

Transgenic overexpression of ribonucleotide reductase improves cardiac performance.Semantic proximity Read ↗

Creatine kinase adenosine triphosphate and phosphocreatine energy supply in a single kindred of patients with hypertrophic cardiomyopathy.Semantic proximity Read ↗

Skeletal muscle ATP kinetics are impaired in frail mice.Semantic proximity Read ↗

Homeostatic adaptations in brain energy metabolism in mouse models of Huntington disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.